Accordino R. E. et al. (2016)
Psychopharmacological interventions in autism spectrum disorder.
Expert Opinion on Pharmacotherapy
May, 17(7), pp. 937-952.
Aman M. G. et al. (2005)
Acute and long-term safety and tolerability of risperidone in children with autism.
Journal of Child and Adolescent Psychopharmacology
15(6), pp. 869-884
Aman M. G. et al. (2008)
Cognitive effects of risperidone in children with autism and irritable behavior.
Journal of Child and Adolescent Psychopharmacology
18(3), pp. 227-236
Aman M. G. et al. (2009)
Journal of the American Academy of Child and Adolescent Psychiatry
48(12), pp. 1143-1154
Aman M. G. et al. (2015)
Journal of Child and Adolescent Psychopharmacology
August, 25(6), pp. 482-493.
Anderson G. M. et al. (2007)
Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
February, 61(4), pp. 545-550.
Arnold L. E. et al. (2003)
Journal of the American Academy of Child and Adolescent Psychiatry
42(12), pp. 1443-1450
Arnold L. E. et al. (2012)
Journal of the American Academy of Child and Adolescent Psychiatry
51(11), pp. 1173-1184.
Blankenship K. et al. (2011)
Guanfacine, extended, release, two, patients, pervasive, developmental, disorders
Journal of Child and Adolescent Psychopharmacology
21(3), pp. 287-290
Broder-Fingert S. et al. (2016)
A pilot study of autism-specific care plans during hospital admission.
Pediatrics
Carroll D. et al. (2014)
Child and Adolescent Psychiatric Clinics of North America
January, 23(1), pp. 57-72.
A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.
Journal of Clinical Psychiatry
65(1), pp. 1531-1536
Doyle C. A. , McDougle C. J. (2012)
Pharmacotherapy to control behavioral symptoms in children with autism.
Expert Opinion on Pharmacotherapy
13(11), pp. 1615-1629.
Early M. C. et al. (2012)
Case report: 16-year-old male with autistic disorder with preoccupation with female feet.
Journal of Autism and Developmental Disorders
May, 42(6), pp. 1133-1137.
Erickson C. A. et al. (2011)
A prospective open-label study of aripiprazole in fragile X syndrome.
Psychopharmacology (Berl)
July, 216(1), pp. 85-90.